# IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMD

> **NCT02462889** · PHASE2 · COMPLETED · sponsor: **Jeffrey S Heier** · enrollment: 128 (actual)

## Conditions studied

- Age-Related Macular Degeneration

## Interventions

- **DRUG:** Intravitreal aflibercept injection
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02462889
- **Lead sponsor:** Jeffrey S Heier
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2019-03
- **Final completion:** 2019-03
- **Target enrollment:** 128 (ACTUAL)
- **Last updated:** 2025-11-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02462889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02462889, "IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02462889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*